Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14161640 | 0.91 | TTR (0.35) | — | |
| SCHEMBL13325852 | 0.91 | TTR (0.35) | — | |
| SCHEMBL2691142 | 0.79 | — | — | |
| SCHEMBL13059964 | 0.72 | LMNA (0.63) | — | |
| SCHEMBL17427501 | 0.71 | MEN1 (0.36) | — | |
| SCHEMBL16058286 | 0.68 | — | — | |
| SCHEMBL20314444 | 0.68 | — | — | |
| SCHEMBL14007006 | 0.68 | — | — | |
| SCHEMBL602269 | 0.67 | — | — | |
| SCHEMBL3084499 | 0.67 | CYP2C19 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050222197-A1 | Novel pyrazolopyridine derivatives as pharmaceutical agents | BEIGHT DOUGLAS W | 2005-10-06 | — | — | US | claimed |
| EP-1543001-A1 | NOVEL PYRAZOLOPYRIDINE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2005-06-22 | — | — | EP | claimed |
| WO-2004026871-A1 | NOVEL PYRAZOLOPYRIDINE DERIVATVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | claimed |
| US-11613544-B2 | Substituted imidazo[1,5-a]pyrazines for modulation of IRE1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-28 | — | — | US | disclosed |
| US-20230002387-A1 | 2-AMINO-S6-SUBSTITUTED THIOPURINE COMPOUNDS AS INHIBITORS OF THE ENPP1 PROTEIN | ATEN PORUS LIFESCIENCES PVT. LTD. (IN) | 2023-01-05 | — | — | US | disclosed |
| US-20210155626-A1 | MODULATION OF IRE1 | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2021-05-27 | — | — | US | disclosed |
| US-20210054007-A1 | RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2021-02-25 | — | — | US | disclosed |
| US-10822340-B2 | Substituted imidazolopyrazine compounds and methods of using same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-11-03 | — | — | US | disclosed |
| US-20190084989-A1 | MODULATION OF IRE1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-03-21 | — | — | US | disclosed |
| US-10131668-B2 | Substituted imidazo[1,5-a]pYRAZINES for modulation of IRE1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-11-20 | — | — | US | disclosed |
| EP-2668184-B1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT | PF MEDICAMENT (FR) | 2018-01-10 | — | — | EP | disclosed |
| US-20070293499-A1 | Intracellular Kinase Inhibitors | MANNKIND CORPORATION (US) | 2007-12-20 | — | — | US | disclosed |
| EP-1814893-A2 | NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| US-7166586-B2 | Sulfonamide lactam inhibitors of FXa and method | BRISTOL MYERS SQUIBB CO. (US) | 2007-01-23 | — | — | US | disclosed |
| US-7166586-B2 | Sulfonamide lactam inhibitors of FXa and method | BRISTOL MYERS SQUIBB CO. (US) | 2007-01-23 | — | — | US | disclosed |
| WO-2006055070-A2 | NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| US-20050222197-A1 | Novel pyrazolopyridine derivatives as pharmaceutical agents | BEIGHT DOUGLAS W | 2005-10-06 | — | — | US | disclosed |
| EP-1543001-A1 | NOVEL PYRAZOLOPYRIDINE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004026871-A1 | NOVEL PYRAZOLOPYRIDINE DERIVATVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | disclosed |
| US-20030050299-A1 | An intermediates for enantiomeric synthesis cermamide-like inhibitors; producing antilipemic agents | GENZYME CORPORATION | 2003-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293499-A1 | Intracellular Kinase Inhibitors | PI4KB, BTK, LTK | DYRK1A 640/4885 |
| US-20230002387-A1 | 2-AMINO-S6-SUBSTITUTED THIOPURINE COMPOUNDS AS INHIBITORS OF THE ENPP1 PROTEIN | ENPP1, ENPP3, PNP | DYRK1A 2439/4885 |
| US-20190084989-A1 | MODULATION OF IRE1 | XBP1, HSPA5, ERN2 | DYRK1A 3791/4885 |
| US-10131668-B2 | Substituted imidazo[1,5-a]pYRAZINES for modulation of IRE1 | XBP1, HSPA5, ERN2 | DYRK1A 2472/4885 |
| US-10822340-B2 | Substituted imidazolopyrazine compounds and methods of using same | HSPA5, XBP1, ERN2 | DYRK1A 2523/4885 |
| US-11613544-B2 | Substituted imidazo[1,5-a]pyrazines for modulation of IRE1 | XBP1, HSPA5, ATF4 | DYRK1A 3785/4885 |
| US-20210054007-A1 | RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | TACR1, TACR2, GPBAR1 | DYRK1A 1505/4885 |
| US-20210155626-A1 | MODULATION OF IRE1 | XBP1, HSPA5, ERN2 | DYRK1A 3791/4885 |
| US-20050222197-A1 | Novel pyrazolopyridine derivatives as pharmaceutical agents | TGFB2, TGFB1, TGFBR1 | DYRK1A 2907/4885 |
| US-20030050299-A1 | An intermediates for enantiomeric synthesis cermamide-like inhibitors; producing antilipemic agents | UGCG, UGGT1, LCLAT1 | DYRK1A 3909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.